Modification of Polylactic acid (PLA), a biopolymer, is a strategy still to be fully explored for the next generation of bioresorbable vascular stent (BVS) biomaterials. With this focus, inclusions upto 5% of Polycaprolactone (PCL) and Magnesium in PLA were tested in the rat subcutaneous model and their cellular and tissue interactions characterized, specifically with respect to inflammatory response, angiogenesis and capsularization. The cytokines IL6, TNF Alpha and IL-1Beta were estimated in the peri-implant tissue, all of which showed a non-significant difference between the non-implanted animals and those containing PLA by 8 weeks, speaking to the benign nature of PLA as an implant biomaterial. Both modified materials, had increased macrophage counts and cytokine levels, except IL6 at 8 weeks. Vascularization only at 8 weeks in PLA PCL containing tissue was significantly higher than pure PLA, which may be more carefully controlled along with the material hydrophobicity for possible efforts towards therapeutic angiogenesis. Capsule thickness, measured by staining with both Hematoxylin & Eosin and Masson’s Trichome did not show any differences between materials, including PLA.

生物聚合物聚乳酸（PLA）的改性是下一代生物可吸收血管支架（BVS）生物材料仍有待充分探索的策略。以此为重点，在大鼠皮下模型中测试了 PLA 中高达 5% 的聚己内酯 (PCL) 和镁，并对其细胞和组织相互作用进行了表征，特别是在炎症反应、血管生成和胶囊化方面。在种植体周围组织中估计了细胞因子 IL6、TNF α 和 IL-1Beta，所有这些在 8 周时都显示非植入动物与含有 PLA 的动物之间没有显着差异，这说明 PLA 的良性性质为一种植入生物材料。两种改性材料均增加了巨噬细胞计数和细胞因子水平，但 8 周时的 IL6 除外。仅在 8 周时，含 PLA PCL 的组织中的血管化显着高于纯 PLA，这可能与材料疏水性一起得到更仔细的控制，以便可能为治疗性血管生成做出努力。通过苏木精和伊红染色以及马森毛状体染色测量的胶囊厚度在材料（包括 PLA）之间没有显示任何差异。